SEARCH

SEARCH BY CITATION

Keywords:

  • minocycline;
  • Huntington's disease;
  • caspase inhibition;
  • apoptosis;
  • neuroprotection

Abstract

Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society